The MHRA is following the EMA by withdrawing Amgen’s Tavneos (avacopan) and banning new patient use as of Sept. 1. Supplies will remain available for about six months to help vasculitis patients transition to alternative treatments. The joint EU/UK action tightens the regulatory environment around complement C5a inhibition and increases operational pressure for physicians managing vasculitis regimens. For Amgen, the withdrawal represents a meaningful commercial hit and forces re-routing of both patient access pathways and payer coverage decisions in affected jurisdictions.